EUVIMEDEUVIMED entdecken
Crossref

Targeted Tumor Microenvironment Delivery of Floxuridine Prodrug via Soluble Silica Nanoparticles in Malignant Melanoma as a Model for Aggressive Cancer Treatment

Andrés Ramos-Valle iD, Arnau Domínguez iD, Natalia Navarro iD, Ana Márquez-López iD, Anna Aviñó iD, Ramon Eritja iD, Carme Fàbrega iD, Lorena García-Hevia iD, Mónica L Fanarraga iD

Small · 2025

DOI: 10.1002/smll.202407752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Andrés Ramos-Valle und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Nanomedicine Group, Instituto de Investigación Valdecilla-IDIVAL, Santander, 39011, Spain. Hauptthemen laut MEDLINE: Prodrugs, Tumor Microenvironment, Nanoparticles, Silicon Dioxide. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: European Regional Development Fund, Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant melanoma presents a significant challenge in oncology due to its aggressive nature and high metastatic potential. Conventional systemic treatments often fail to effectively reach tumor sites, limiting their therapeutic impact. This study introduces a groundbreaking triple‐strategy approach for treating malignant melanoma. A novel prodrug, an oligonucleotide, comprising 10 units of Floxuridine (5‐fluoro‐2′‐deoxyuridine) (FdU) nucleoside antimetabolites are developed, to enhance half‐life and reduce rapid metabolism. Encapsulated in soluble colloidal silica nanoparticles, this compound is protected and directed toward tumor neovasculature precursor endothelial cell receptors, ensuring local delivery. The strategy focuses on releasing the prodrug in the tumor microenvironment, aiming to eradicate both melanoma cells and their supportive structures. Efficacy is demonstrated in cell culture studies and preclinical models of malignant melanoma, showing a remarkable 50% reduction in tumor size after just three intravenous treatments. These findings underscore the transformative potential of targeting endothelial cell membrane proteins for drug delivery. This study paves the way for innovative targeted therapies, promising significant advancements in treatment strategies and improves outcomes for patients with metastatic cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsTumor MicroenvironmentNanoparticlesSilicon DioxideFloxuridineMelanomaDrug Delivery SystemsAnimalsHumansCell Line, TumorMiceSolubility

Stichwörter der Autor:innen

TEM8VEGF receptormalignant melanomasilica nanoparticlestargeted deliverytherapeutic oligonucleotidetumor neovasculature

Substanzen

ProdrugsSilicon DioxideFloxuridine

Autor:innen und Institutionen

  • The Nanomedicine Group, Instituto de Investigación Valdecilla-IDIVAL, Santander, 39011, Spain.
  • Department of Molecular Biology, Faculty of Medicine, Universidad de Cantabria, Santander, 39011, Spain.
  • Dpt. Surfactants & Nanobiotechnology, Institute for Advanced Chemistry of Catalonia (IQAC), CSIC, Barcelona, 08034, Spain.
  • CIBER-BBN Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Barcelona, 08034, Spain.

ORCID-Profile: Andrés Ramos-Valle, Arnau Domínguez, Natalia Navarro, Ana Márquez-López, Anna Aviñó, Ramon Eritja, Carme Fàbrega, Lorena García-Hevia, Mónica L Fanarraga

Förderung

  • European Regional Development Fund
  • Ministerio de Ciencia e Innovación
  • Instituto de Salud Carlos III

Zitieren

APA

Ramos-Valle, A., Domínguez, A., Navarro, N., Márquez-López, A., Aviñó, A., Eritja, R., Fàbrega, C., García-Hevia, L., & Fanarraga, M. L. (2025). Targeted Tumor Microenvironment Delivery of Floxuridine Prodrug via Soluble Silica Nanoparticles in Malignant Melanoma as a Model for Aggressive Cancer Treatment. Small. https://doi.org/10.1002/smll.202407752

Vancouver

Ramos-Valle A, Domínguez A, Navarro N, Márquez-López A, Aviñó A, Eritja R, et al. Targeted Tumor Microenvironment Delivery of Floxuridine Prodrug via Soluble Silica Nanoparticles in Malignant Melanoma as a Model for Aggressive Cancer Treatment. Small. 2025. doi:10.1002/smll.202407752

BibTeX
@article{RamosValle2025,
  author = {Ramos-Valle, Andrés and Domínguez, Arnau and Navarro, Natalia and Márquez-López, Ana and Aviñó, Anna and Eritja, Ramon and Fàbrega, Carme and García-Hevia, Lorena and Fanarraga, Mónica L},
  title = {Targeted Tumor Microenvironment Delivery of Floxuridine Prodrug via Soluble Silica Nanoparticles in Malignant Melanoma as a Model for Aggressive Cancer Treatment},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202407752}
}
Kostenlos starten →